HopeStage
Back to all studies
RecruitingNCT06502964

ALTO-101 or placebo patch for cognition in people with schizophrenia

About this titleRead the official source — NCT06502964
Medication studyAges 21–55United States
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 21 years to 55 years. Other eligibility criteria apply.

Listed locations
Garden Grove and 13 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 11, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
82
Sponsor
Alto Neuroscience
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Device, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 21 Years to 55 Years
Official registry ID
NCT06502964
Official title
Show the full official title

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Recruitment & locations

Currently recruiting

Garden Grove · Los Angeles · Orange

9 more locations
  • Walnut Creek
  • Hollywood
  • Tampa
  • Snellville
  • Chicago
  • Gaithersburg
  • Belmont
  • New York
  • White Plains

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alto Neuroscience.

Does this study involve medication?

Yes. The study involves medication, including ALTO-101 and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 21 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies